Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000116

Senior Vice President, Finance sold 10,000 shares at an average $104.97 ($1,049,658)

  • Senior Vice President, Finance acquired 10,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Option exercise 10b5-1 +8,542 $12.50 $106,775 22,761 D: show line 1 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Option exercise 10b5-1 +1,458 $34.39 $50,141 24,219 D: show line 2 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Sale 10b5-1 −500 $101.98 $50,988 23,719 D: show line 3 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Sale 10b5-1 −801 $103.16 $82,628 22,918 D: show line 4 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Sale 10b5-1 −799 $104.25 $83,296 22,119 D: show line 5 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Sale 10b5-1 −6,842 $105.28 $720,330 15,277 D: show line 6 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Sale 10b5-1 −958 $106.18 $101,717 14,319 D: show line 7 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Sale 10b5-1 −100 $107.00 $10,700 14,219 D: show line 8 in the form
Open-market sales · 10,000 sh · avg $104.97 · $1,049,658

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Option exercise · Employee Stock Option (right to buy) 10b5-1 −8,542 67,834 D: show line 9 in the form
Agarwal Arjun Senior Vice President, Finance 2026-11-12 Option exercise · Employee Stock Option (right to buy) 10b5-1 −1,458 55,417 D: show line 10 in the form
Loading xslF345X06/form4.xml…